Literature DB >> 34143685

A Single Inhaler Combining a Corticosteroid and Long-Acting Beta-2 Agonist for Maintenance with Additional Doses for Reliever Therapy (SMART): Obstacles for Asthma Patients in the USA.

Leslie Hendeles1, Kathryn V Blake2, Ashley Galbreath3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34143685      PMCID： PMC8329725          DOI： 10.1089/ped.2021.0052

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol Pulmonol        ISSN： 2151-321X            Impact factor:   0.885


× No keyword cloud information.
  9 in total

1.  Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients.

Authors:  M Palmqvist; T Ibsen; A Mellén; J Lötvall
Journal:  Am J Respir Crit Care Med       Date:  1999-07       Impact factor: 21.405

Review 2.  Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis.

Authors:  Diana M Sobieraj; Erin R Weeda; Elaine Nguyen; Craig I Coleman; C Michael White; Stephen C Lazarus; Kathryn V Blake; Jason E Lang; William L Baker
Journal:  JAMA       Date:  2018-04-10       Impact factor: 56.272

3.  Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI.

Authors:  L Thorsson; S Edsbäcker; T B Conradson
Journal:  Eur Respir J       Date:  1994-10       Impact factor: 16.671

4.  Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency.

Authors:  M Palmqvist; G Persson; L Lazer; J Rosenborg; P Larsson; J Lötvall
Journal:  Eur Respir J       Date:  1997-11       Impact factor: 16.671

5.  Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma.

Authors:  Hans Bisgaard; Pascal Le Roux; Ditlef Bjåmer; Andrzej Dymek; Jan H Vermeulen; Christer Hultquist
Journal:  Chest       Date:  2006-12       Impact factor: 9.410

6.  Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial.

Authors:  Mitesh Patel; Janine Pilcher; Alison Pritchard; Kyle Perrin; Justin Travers; Dominick Shaw; Shaun Holt; Matire Harwood; Peter Black; Mark Weatherall; Richard Beasley
Journal:  Lancet Respir Med       Date:  2013-03-04       Impact factor: 30.700

7.  Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone.

Authors:  Jean Bousquet; Louis-Philippe Boulet; Matthew J Peters; Helgo Magnussen; Joaquin Quiralte; Nora E Martinez-Aguilar; Asa Carlsheimer
Journal:  Respir Med       Date:  2007-10-01       Impact factor: 3.415

Review 8.  2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group.

Authors:  Michelle M Cloutier; Alan P Baptist; Kathryn V Blake; Edward G Brooks; Tyra Bryant-Stephens; Emily DiMango; Anne E Dixon; Kurtis S Elward; Tina Hartert; Jerry A Krishnan; Robert F Lemanske; Daniel R Ouellette; Wilson D Pace; Michael Schatz; Neil S Skolnik; James W Stout; Stephen J Teach; Craig A Umscheid; Colin G Walsh
Journal:  J Allergy Clin Immunol       Date:  2020-12       Impact factor: 10.793

9.  Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations.

Authors:  P Kuna; M J Peters; A I Manjra; C Jorup; I P Naya; N E Martínez-Jimenez; R Buhl
Journal:  Int J Clin Pract       Date:  2007-03-16       Impact factor: 2.503
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.